Cargando…
Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modelling approaches are widely accepted in non-radiopharmaceutical drug development and research, while there is no major role for these approaches in radiopharmaceutical development yet. In this review, a l...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706588/ https://www.ncbi.nlm.nih.gov/pubmed/36451855 http://dx.doi.org/10.7150/thno.77279 |
_version_ | 1784840537312854016 |
---|---|
author | Siebinga, Hinke de Wit-van der Veen, Berlinda J. Stokkel, Marcel D.M. Huitema, Alwin D.R. Hendrikx, Jeroen J.M.A. |
author_facet | Siebinga, Hinke de Wit-van der Veen, Berlinda J. Stokkel, Marcel D.M. Huitema, Alwin D.R. Hendrikx, Jeroen J.M.A. |
author_sort | Siebinga, Hinke |
collection | PubMed |
description | Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modelling approaches are widely accepted in non-radiopharmaceutical drug development and research, while there is no major role for these approaches in radiopharmaceutical development yet. In this review, a literature search was performed to specify different research purposes and questions that have previously been answered using both PBPK and population PK modelling for radiopharmaceuticals. Methods: The literature search was performed using the databases PubMed and Embase. Wide search terms included radiopharmaceutical, tracer, radioactivity, physiologically based pharmacokinetic model, PBPK, population pharmacokinetic model and nonlinear mixed-effects model. Results: Eight articles and twenty articles were included for this review based on this literature search for population PK modelling and PBPK modelling, respectively. Included population PK analyses showed to have an added value to develop predictive models for a population and to describe individual variability sources. Main purposes of PBPK models appeared related to optimizing treatment (planning), or more specifically: to find the optimal combination of peptide amount and radioactivity, to optimize treatment planning by reducing the number of measurements, to individualize treatment, to get insights in differences between pre-therapeutic and therapeutic scans or to understand inter-patient differences. Other main research subjects were regarding radiopharmaceutical comparisons, selecting ligands based on their peptide characteristics and gaining a better understanding of drug-drug interactions. Conclusions: The use of PK modelling approaches in radiopharmaceutical research remains scarce, but can be expanded to obtain a better understanding of PK and whole-body distribution of radiopharmaceuticals in general. PK modelling of radiopharmaceuticals has great potential for the nearby future and could contribute to the evolving research of radiopharmaceuticals. |
format | Online Article Text |
id | pubmed-9706588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-97065882022-11-29 Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review Siebinga, Hinke de Wit-van der Veen, Berlinda J. Stokkel, Marcel D.M. Huitema, Alwin D.R. Hendrikx, Jeroen J.M.A. Theranostics Review Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modelling approaches are widely accepted in non-radiopharmaceutical drug development and research, while there is no major role for these approaches in radiopharmaceutical development yet. In this review, a literature search was performed to specify different research purposes and questions that have previously been answered using both PBPK and population PK modelling for radiopharmaceuticals. Methods: The literature search was performed using the databases PubMed and Embase. Wide search terms included radiopharmaceutical, tracer, radioactivity, physiologically based pharmacokinetic model, PBPK, population pharmacokinetic model and nonlinear mixed-effects model. Results: Eight articles and twenty articles were included for this review based on this literature search for population PK modelling and PBPK modelling, respectively. Included population PK analyses showed to have an added value to develop predictive models for a population and to describe individual variability sources. Main purposes of PBPK models appeared related to optimizing treatment (planning), or more specifically: to find the optimal combination of peptide amount and radioactivity, to optimize treatment planning by reducing the number of measurements, to individualize treatment, to get insights in differences between pre-therapeutic and therapeutic scans or to understand inter-patient differences. Other main research subjects were regarding radiopharmaceutical comparisons, selecting ligands based on their peptide characteristics and gaining a better understanding of drug-drug interactions. Conclusions: The use of PK modelling approaches in radiopharmaceutical research remains scarce, but can be expanded to obtain a better understanding of PK and whole-body distribution of radiopharmaceuticals in general. PK modelling of radiopharmaceuticals has great potential for the nearby future and could contribute to the evolving research of radiopharmaceuticals. Ivyspring International Publisher 2022-11-14 /pmc/articles/PMC9706588/ /pubmed/36451855 http://dx.doi.org/10.7150/thno.77279 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Siebinga, Hinke de Wit-van der Veen, Berlinda J. Stokkel, Marcel D.M. Huitema, Alwin D.R. Hendrikx, Jeroen J.M.A. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
title | Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
title_full | Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
title_fullStr | Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
title_full_unstemmed | Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
title_short | Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
title_sort | current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706588/ https://www.ncbi.nlm.nih.gov/pubmed/36451855 http://dx.doi.org/10.7150/thno.77279 |
work_keys_str_mv | AT siebingahinke currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview AT dewitvanderveenberlindaj currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview AT stokkelmarceldm currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview AT huitemaalwindr currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview AT hendrikxjeroenjma currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview |